Yes or no to local therapy for oligometastatic prostate cancer?
Crossref DOI link: https://doi.org/10.1038/s41585-018-0028-7
Published Online: 2018-05-23
Published Print: 2018-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Moul, Judd W.
Text and Data Mining valid from 2018-05-23
Article History
First Online: 23 May 2018
Competing interests
: The author declares research support from and has acted as an adviser or speaker for Astellas, Bayer, Dendreon, Janssen, Ferring, Pfizer, and Sanofi.